Exploring Immune Responses in Tonsil Organoids: A Study on Host-Pathogen Interactions

This groundbreaking observational study aims to revolutionize our understanding of host-pathogen interactions by developing innovative lymphoid organoid models from discarded human tonsil tissues. The research focuses particularly on the human immune response to the Chemotaxis Inhibitory Protein of Staphylococcus aureus (CHIPS), a key virulence factor in staphylococcal infections.

Primary Study Objectives:

  • Establish functional lymphoid organoid models using routinely discarded tonsil tissues from tonsillectomy procedures
  • Characterize human immune responses to primary, repeated, and re-exposure to CHIPS within antigenic sin contexts
  • Investigate mechanisms of immunotolerance to this important bacterial virulence factor

Secondary Objectives:

  • Explore how variations in primary and co-stimulatory signals affect IgG4 class switching in response to CHIPS
  • Identify potential modulators of immune tolerance pathways

The study will enroll approximately 500 participants aged 2 years and older who are undergoing routine tonsillectomy procedures at US hospitals and ENT practices. Using advanced techniques including single-cell analysis of class switch recombination (sciCSR) and measurement of activation-induced cytidine deaminase (AID) levels, researchers will generate comprehensive immunologic profiles.

Key Measurements:

  1. Detailed immune cell composition analysis
  2. Quantification of anti-CHIPS antibody levels and subclasses
  3. Cytokine profiling
  4. Molecular markers of class switching

This NIH/NIAID-sponsored research has significant potential to advance our understanding of immune responses to S. aureus infections and may lead to new therapeutic approaches for modulating immunotolerance. The study will run from May 2025 through December 2043 under the leadership of Dr. Michael Otto at the National Institute of Allergy and Infectious Diseases.

Participants will contribute to this important research simply by allowing the use of tissue that would otherwise be discarded after their clinically indicated tonsillectomy. The study excludes individuals with active infections, immunosuppression, or other conditions that might compromise tissue quality for the intended research purposes.

Upcoming Clinical Trials

Subscribe